Annual General Meeting 2020

Annual General Meeting 2020

Annual General Meeting 2020

BioNTech's Annual General Meeting was held on Tuesday 26 June 2021, online, without shareholders or their proxies present, with 82.08 per cent of the registered share capital represented. The shareholders approved all resolutions. The voting results can be found on this page.

 

Annual General Meeting 2020 Voting Results 2020

Annual General Meeting 2020 Voting Results

 

Presentations and Speeches

Speech of Prof. Dr. Ugur Sahin (CEO)

Speech of Dr. Sierk Poetting (COO/CFO)

 

INFORMATION AND DOCUMENTS FOR THE VIRTUAL ANNUAL GENERAL MEETING

Invitation to the Annual General Meeting 2020

 

Documents on Agenda Item 1

BioNTech SE Annual Financial Statements 2019 Convenience Translation

BioNTech SE Consolidated Financial Statements 2019 Convenience Translation

BioNTech SE Combined Management Report 2019 Convenience Translation

Report of the Supervisory Board on the 2019 Financial Year Convenience Translation

 

Explanation to Agenda Item 1

Explanatory Notes on Agenda Item 1 Sec. 124a Sentence 1 No. 2 Stock Corporation Act (AktG)

 

Report of the Management Board on Agenda Item 6 (Exclusion of Subscription Rights)

Report of the Management Board on Agenda Item 6 Sec. 186 Para. 4 Sentence No. 2 Stock Corporation Act (AktG)

 

Documents on Agenda Items 6 and 7

BioNTech SE Articles of Association Convenience Translation

 

Documents on Agenda Item 8

Sample Domination Agreement Convenience Translation

Sample Domination and Profit and Loss Transfer Agreement Convenience Translation

 

BioNTech IVAC GmbH

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and BioNTech IVAC GmbH for the Domination Agreement

BioNTech IVAC GmbH Closing Balance Sheet and Profit and Loss 2017 to 2019

 

BioNTech Real Estate Holding GmbH

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and BioNTech Real Estate Holding GmbH for the Domination Agreement

BioNTech Real Estate Holding GmbH Closing Balance Sheet and Profit and Loss 2017 to 2019

 

BioNTech Small Molecules GmbH

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and BioNTech Small Molecules GmbH for the Domination Agreement

BioNTech Small Molecules GmbH Closing Balance Sheet and Profit and Loss 2017 to 2019

 

BioNTech Cell & Gene GmbH

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and BioNTech Cell & Gene GmbH for the Domination and Profit and Loss Transfer Agreement

BioNTech Cell & Gene GmbH Closing Balance Sheet and Profit and Loss 2017 to 2019

 

JPT Peptide Technologies GmbH

Joint Report pursuant to Sec. 293 Stock Corporation Act of BioNTech SE and JPT Peptide Technologies GmbH for the Domination and Profit and Loss Transfer Agreement

JPT Peptide Technologies GmbH Closing Balance Sheet and Profit and Loss 2017 to 2019

 

Further Documents and Forms

Explanation of Shareholder Rights

Registration, Voting and Proxy Form

Notes on Data Protection

 

Total Number of Shares and Voting Rights

Total Number of Shares and Voting Rights

 

Countermotions and Election Proposals

There were no countermotions and election proposals from shareholders.